Navigation Links
O'Gawa-Utrata Capsulorhexis Forceps

ProductsO'Gawa-Utrata Capsulorhexis Forceps
Company Bausch & Lomb Storz
Item O'Gawa-Utrata Capsulorhexis Forceps
Features 
Description Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish.
Info Bausch & Lomb Storz
Customer Service: (585) 338-6000
Web site: http://www.storz.com/

Related medicine products :

1. Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g
2. Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g
3. Capsulorhexis Forceps Sharp Tip
4. Maloney Capsulorhexis Forceps
5. Gimbel Capsulorhexis Forceps
6. Lehner Capsulorhexis Forceps
7. Koch Capsulorhexis Forceps
8. Utrata Capsulorhexis Forceps
9. Peirse Tip Capsulorhexis Forceps
10. Kellan Capsulorhexis Forceps
11. Lehner-Utrata Capsulorhexis Forceps
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...ernational Association for Dental Research, scient...ical //detection of major human diseases is only a...scover diagnostic saliva biomarkers. A necessary p..., the informative biomarkers in saliva: the diagno...
...d psychotherapy soon after starting on antidepress...inue// 18 months after their first session. So con...f Consulting and Clinical Psychology. This paper ...ince a 2004 Journal of the American Medical Associ...
...with arterial disease have relatively high risk of...art attack, stroke or cardiovascular death) within... issue of JAMA. Atherothrombosis (arterial diseas..., cerebrovascular disease [CVD], and peripheral ar...
...ge their emotions is just as important as providin...afe sex// in order to prevent HIV and other sexual...rs for Disease Control (CDC), adolescents and youn...ercent of new HIV infections on an annual basis. A...
Other Medicine News:Health News:Phone-based Therapy Eases Depression Long Term 2Health News:Phone-based Therapy Eases Depression Long Term 3Health News:Atherothrombosis Patients at High Risk for CV Events 2Health News:Managing Emotions to Prevent HIV 2
(Date:10/7/2008)...ire/ -- A study published in the,scientific journa...l,reported that InVitria,s ( http://www.InVitria....was an effective replacement to bovine serum album...e ground state of embryonic stem cell,self-renewal...recombinant,albumin in place of animal-derived ser...
(Date:10/7/2008).../ -- Taligen Therapeutics Inc.,today announced tha...e,candidates were presented at the XXII Internatio... data highlighted the candidates, efficacy in,seve..., "These highlighted presentations, as well as se..., reveal the deep expertise and expanding,knowledg...
(Date:10/7/2008)...A,s long-term benefits and value in,moderate to se...n College,of Gastroenterology (ACG), ORLANDO, Fla...tudies,presented this week by UCB at the American ...emonstrate that CIMZIA(R) (certolizumab pegol) - t...actor alpha) - provides,sustained improvement in s...
(Date:10/7/2008)...all/ -- Ardea Biosciences, Inc.,(Nasdaq: RDEA ) a...Potent,and Highly Selective MEK1/2 Inhibitor is Be...d Chronic Colitis in Mice," was presented at the,A...ual Meeting in Orlando,Florida. The poster, which..., the Company,s lead mitogen-activated ERK kinase ...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4MacroChem Acquires Virium Pharmaceuticals 4805 1MacroChem Acquires Virium Pharmaceuticals 4805 2MacroChem Acquires Virium Pharmaceuticals 4805 3MacroChem Acquires Virium Pharmaceuticals 4805 4MacroChem Acquires Virium Pharmaceuticals 4805 5Genzyme Reports Strong First Quarter Growth 4802 1Genzyme Reports Strong First Quarter Growth 4802 2Genzyme Reports Strong First Quarter Growth 4802 3Genzyme Reports Strong First Quarter Growth 4802 4Genzyme Reports Strong First Quarter Growth 4802 5Genzyme Reports Strong First Quarter Growth 4802 6Genzyme Reports Strong First Quarter Growth 4802 7Genzyme Reports Strong First Quarter Growth 4802 8Genzyme Reports Strong First Quarter Growth 4802 9Genzyme Reports Strong First Quarter Growth 4802 10Genzyme Reports Strong First Quarter Growth 4802 11Genzyme Reports Strong First Quarter Growth 4802 12Genzyme Reports Strong First Quarter Growth 4802 13Genzyme Reports Strong First Quarter Growth 4802 14Genzyme Reports Strong First Quarter Growth 4802 15Genzyme Reports Strong First Quarter Growth 4802 16Genzyme Reports Strong First Quarter Growth 4802 17Genzyme Reports Strong First Quarter Growth 4802 18Genzyme Reports Strong First Quarter Growth 4802 19PTC Therapeutics Announces Initiation of Phase 2b Registration Directed Clinical Trial of PTC124 in Duchenne Becker Muscular Dystrophy 1881 1PTC Therapeutics Announces Initiation of Phase 2b Registration Directed Clinical Trial of PTC124 in Duchenne Becker Muscular Dystrophy 1881 2PTC Therapeutics Announces Initiation of Phase 2b Registration Directed Clinical Trial of PTC124 in Duchenne Becker Muscular Dystrophy 1881 3PTC Therapeutics Announces Initiation of Phase 2b Registration Directed Clinical Trial of PTC124 in Duchenne Becker Muscular Dystrophy 1881 4PTC Therapeutics Announces Initiation of Phase 2b Registration Directed Clinical Trial of PTC124 in Duchenne Becker Muscular Dystrophy 1881 5Sleep Apnea Screening Cuts Surgical Complications 17520 1Sleep Apnea Screening Cuts Surgical Complications 17520 2
... STANFORD, Calif.--(BUSINESS WIRE)--Apr 10, 2007 -...tardation, Fragile X and Down,syndromes, may share...ord University School of Medicine. The problem, a ...lso be associated with,autism., Although the genet...esult for the brain seems to be the same, said Dan...
... Additional Preclinical Data Presented on Valopici...nhibitor, BARCELONA, Spain, April 12, 2007 /PRNews...day announced results from two phase,IIb studies o...and,pegylated interferon alfa-2a (Pegasys(R)) in b...ients infected with the genotype-1,strain of the h...
Other Medicine Technology:Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7